Outcome-Driven Thresholds for Ambulatory Blood Pressure Based on the New American College of Cardiology/American Heart Association Classification of Hypertension

Author:

Cheng Yi-Bang1,Thijs Lutgarde2,Zhang Zhen-Yu2,Kikuya Masahiro3,Yang Wen-Yi2,Melgarejo Jesus D.4,Boggia José5,Wei Fang-Fei2,Hansen Tine W.6,Yu Cai-Guo2,Asayama Kei37,Ohkubo Takayoshi37,Dolan Eamon8,Stolarz-Skrzypek Katarzyna9,Malyutina Sofia10,Casiglia Edoardo11,Lind Lars12,Filipovský Jan13,Maestre Gladys E.414,Imai Yutaka7,Kawecka-Jaszcz Kalina9,Sandoya Edgardo15,Narkiewicz Krzysztof16,Li Yan1,O’Brien Eoin17,Wang Ji-Guang1,Staessen Jan A.218,

Affiliation:

1. From the Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (Y.-B.C., Y.L., J.-G.W.)

2. Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (L.T., Z.-Y.Z., W.-Y.Y., F.-F.W., C.-G.Y., J.A.S.)

3. Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (M.K., K.A., T.O.)

4. Laboratorio de Neurociencias and Instituto de Enfermedades Cardiovasculares, Universidad del Zulia, Maracaibo, Venezuela (J.D.M., G.E.M.)

5. Centro de Nefrología and Departamento de Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay (J.B.)

6. Steno Diabetes Center, Copenhagen, Gentofte, and Center for Health, Capital Region of Denmark, Denmark (T.W.H.)

7. Department of Planning for Drug Development and Clinical Evaluation, Tohoku Institute for Management of Blood Pressure, Sendai, Japan (K.A., T.O., Y.I.)

8. Stroke and Hypertension Unit, Blanchardstown, Dublin, Ireland (E.D.)

9. First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Krakow, Poland (K.S.-S., K.K.-J)

10. Institute of Internal and Preventive Medicine, Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russian Federation (S.M.)

11. Department of Medicine, University of Padua, Italy (E.C.)

12. Section of Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Sweden (L.L.)

13. Faculty of Medicine, Charles University, Pilsen, Czech Republic (J.F.)

14. Department of Neurosciences and Department of Human Genetics, University of Texas Rio Grande Valley School of Medicine, Brownsville (G.E.M.)

15. Asociación Española Primera de Socorros Mutuos, Montevideo, Uruguay (E.S.)

16. Department of Hypertension and Diabetology, Hypertension Unit, Medical University of Gdańsk, Poland (K.N.)

17. Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Ireland (E.O.)

18. Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands (J.A.S.).

Abstract

The new American College of Cardiology/American Heart Association guideline reclassified office blood pressure and proposed thresholds for ambulatory blood pressure (ABP). We derived outcome-driven ABP thresholds corresponding with the new office blood pressure categories. We performed 24-hour ABP monitoring in 11 152 participants (48.9% women; mean age, 53.0 years) representative of 13 populations. We determined ABP thresholds resulting in multivariable-adjusted 10-year risks similar to those associated with elevated office blood pressure (120/80 mm Hg) and stages 1 and 2 of office hypertension (130/80 and 140/90 mm Hg). Over 13.9 years (median), 2728 (rate per 1000 person-years, 17.9) people died, 1033 (6.8) from cardiovascular disease; furthermore, 1988 (13.8), 893 (6.0), and 795 (5.4) cardiovascular and coronary events and strokes occurred. Using a composite cardiovascular end point, systolic/diastolic outcome-driven thresholds indicating elevated 24-hour, daytime, and nighttime ABP were 117.9/75.2, 121.4/79.6, and 105.3/66.2 mm Hg. For stages 1 and 2 ambulatory hypertension, thresholds were 123.3/75.2 and 128.7/80.7 mm Hg for 24-hour ABP, 128.5/79.6 and 135.6/87.1 mm Hg for daytime ABP, and 111.7/66.2 and 118.1/72.5 mm Hg for nighttime ABP. ABP thresholds derived from other end points were similar. After rounding, approximate thresholds for elevated 24-hour, daytime, and nighttime ABP were 120/75, 120/80, and 105/65 mm Hg, and for stages 1 and 2, ambulatory hypertension 125/75 and 130/80 mm Hg, 130/80 and 135/85 mm Hg, and 110/65 and 120/70 mm Hg. Outcome-driven ABP thresholds corresponding to elevated blood pressure and stages 1 and 2 of hypertension are similar to those proposed by the current American College of Cardiology/American Heart Association guideline.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3